Alkem Laboratories Limited

rs,

28th May, 2026 To, The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

40.7%

nce in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healt

36,033 million

markets.” Q4 FY26 Key Financial Highlights (cid:120) Total Revenue from Operations was (cid:3423)36,033 million, with YoY growth of 14.6%. o India sales were (cid:3423)23,245 million, YoY growth of 8.8%. o Inte

14.6%

ighlights (cid:120) Total Revenue from Operations was (cid:3423)36,033 million, with YoY growth of 14.6%. o India sales were (cid:3423)23,245 million, YoY growth of 8.8%. o International sales were (cid:

23,245 million

om Operations was (cid:3423)36,033 million, with YoY growth of 14.6%. o India sales were (cid:3423)23,245 million, YoY growth of 8.8%. o International sales were (cid:3423)12,223 million, with YoY growth of 25.4%.

8.8%

,033 million, with YoY growth of 14.6%. o India sales were (cid:3423)23,245 million, YoY growth of 8.8%. o International sales were (cid:3423)12,223 million, with YoY growth of 25.4%. (cid:120) EBITDA w

12,223 million

India sales were (cid:3423)23,245 million, YoY growth of 8.8%. o International sales were (cid:3423)12,223 million, with YoY growth of 25.4%. (cid:120) EBITDA was (cid:3423)5,174 million, resulting in an EBITDA ma

25.4%

illion, YoY growth of 8.8%. o International sales were (cid:3423)12,223 million, with YoY growth of 25.4%. (cid:120) EBITDA was (cid:3423)5,174 million, resulting in an EBITDA margin of 14.4% vs. 12.4% in

5,174 million

onal sales were (cid:3423)12,223 million, with YoY growth of 25.4%. (cid:120) EBITDA was (cid:3423)5,174 million, resulting in an EBITDA margin of 14.4% vs. 12.4% in Q4 FY25. EBITDA grew by 32.2% YoY. (cid:120

14.4%

oY growth of 25.4%. (cid:120) EBITDA was (cid:3423)5,174 million, resulting in an EBITDA margin of 14.4% vs. 12.4% in Q4 FY25. EBITDA grew by 32.2% YoY. (cid:120) R&D expenses for Q4 (cid:41)(cid:60)(c

12.4%

of 25.4%. (cid:120) EBITDA was (cid:3423)5,174 million, resulting in an EBITDA margin of 14.4% vs. 12.4% in Q4 FY25. EBITDA grew by 32.2% YoY. (cid:120) R&D expenses for Q4 (cid:41)(cid:60)(cid:21)(cid

32.2%

d:3423)5,174 million, resulting in an EBITDA margin of 14.4% vs. 12.4% in Q4 FY25. EBITDA grew by 32.2% YoY. (cid:120) R&D expenses for Q4 (cid:41)(cid:60)(cid:21)(cid:25)(cid:3) (cid:90)(cid:72)(cid:85

“Isha Trivedi +91 98925 90003 alkemcorpcomm@alkem.com +91-22-3982 9999 Ext:9672 Invite for Q4FY26 & FY26 Conference Call at 4.30 pm IST, May 28, 2026 Mumbai, May 20, 2026: Alkem Laboratories Ltd.”

“(NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Thursday, May 28, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q4 and FY26 financial results.”

“The call will follow the announcement of the Company’s Q4 and FY26 financial results on Thursday, May 28, 2026.”

“(cid:131) Domestic revenue contributed 65.5% to total sales in Q4 FY26.”

“(cid:131) According to IQVIA (SSA) data, for Q4 FY26: • The Company registered a growth of 11.1% YoY vs the Indian Pharmaceutical Market (IPM), which grew by 10.1%, 100 bps outperformance.”

“(cid:131) Domestic revenue contributed 67.8% to total sales in FY26.”

“(cid:131) According to IQVIA (SSA) data, for FY26: • The Company registered a growth of 9.2% YoY vs the Indian Pharmaceutical Market (IPM), which grew by 9.0%, 20 bps outperformance.”

“(cid:131) US revenue contributed 21.7% to total sales in Q4 FY26.”

“(cid:131) During the Q4 FY26, received 04 ANDAs approval approvals).”

“(cid:131) US revenue contributed 20.5% to total sales in FY26.”

Investors

1

Media

1

E-mail

1

Investors

Purvi Shah – Head of Investor Relations +91 84337 00890 purvi.shah@alkem.com +91-22-3982 9999 Ext: 9447

Media

Isha Trivedi +91 98925 90003 alkemcorpcomm@alkem.com +91-22-3982 9999 Ext:9672 Invite for Q4FY26 & FY26 Conference Call at 4.30 pm IST, May 28, 2026 Mumbai, May 20, 2026: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Thursday, May 28, 2026, from 4:30 pm to 5:30 pm IST to discuss its Q4 and FY26 financial results. The call will follow the announcement of the Company’s Q4 and FY26 financial results on Thursday, May 28, 2026. Alkem Laboratories Ltd. will be represented on the call by: Mr. Sandeep Singh - MD Dr. Vikas Gupta – CEO, Alkem Laboratories Mr. Nitin Agrawal – CFO Motilal Oswal Securities Ltd will host the call. Details of the conference call are as follows Time 4:30 pm IST (GMT + 5:30) on Thursday, May 28, 2026. Dial in Details India +91 22 6280 1149 / +91 22 7115 8050 International Toll-Free USA 1 866 746 2133 UK 0 808 101 1573 Singapore 800 101 2045 Hong Kong 800 964 448 Express

E-mail

isha.trivedi@alkem.com purvi.shah@alkem.com/ Tushar Manudhane Institutional Research Analyst - Healthcare Motilal Oswal Securities Ltd. Tel.: +91 22 6129 1536 / +91 82911 38039 E-mail: Tushar.Manudhane@motilaloswal.com Alkem Laboratories Ltd. Q4 & FY26 Results Presentation 28th May 2026 1111111111111 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation: • General economic and business conditions in India